newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company's IND Application IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second